Calculare Technologies

Calculare Technologies is a biotechnology company leveraging generative artificial intelligence to design next-generation therapeutics, with a primary focus on peptides and proteins. Founded by researchers from MIT and Harvard, the company's platform is engineered to tackle "undruggable" targets, particularly complex protein-protein interactions involved in disease progression. By integrating advanced computational modeling with experimental validation, Calculare accelerates the identification and optimization of high-affinity binders. The company aims to transform drug discovery from a process of screening to one of intentional design, significantly reducing development timelines. Their current internal pipeline focuses on high-impact areas such as oncology and immunology.